Preclinical and clinical studies have demonstrated the synergistic effect of CDKs inhibitors with anti-estrogen agents, probably due to the special dependence of ER+ BC cells on cyclin D1 and estrogen-mediated activation of CDKs 96. Here, ESR1 is linked to breast cancer.